ABSTRACT
Background: Anaemia and transfusions are frequent in critically ill patients and there are avoidable causes such as routine laboratory tests. Patients and methods: Descriptive study during one continuous week including patients over 18-years old in a medical-surgical ICU. Results: 18 patients were included during a week in 12 beds in our unit, median age 62,5 years, 50% male. Median daily blood loss was 35ml, 45% in laboratory samples and 27% related to renal replacement therapy. 3 patients required 1 transfusion of red blood cells. Conclusions: There is a pattern of continuous blood loss in critically ill patients, primarily in routine laboratory tests. (AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Hemorrhage/etiology , Intensive Care Units , Blood Transfusion , Hemorrhage/epidemiology , Anemia/complicationsABSTRACT
Resumen Antecedentes y objetivo: El interés sobre la influencia del sexo en pacientes con síndrome coronario agudo (SCA) tratados con stent y nuevos antiagregantes inhibidores de P2Y12 en la práctica clínica es creciente. Se analizan las diferencias en función del sexo en el tratamiento con doble antiagregación plaquetaria (DAPT) y los eventos adversos isquémicos y hemorrágicos Materiales y métodos: Estudio prospectivo de pacientes consecutivos con diagnóstico de SCA tratados con stent coronario desde julio de 2015 hasta enero de 2016. Resultados: De un total de 283 pacientes incluidos, 75 (26.5%) correspondió a mujeres y 208 (73.5%) a hombres. La edad media fue de 71 ± 13 y 66.5 ± 13 años, respectivamente. Un 44% de mujeres se presentó como SCA con elevación del segmento ST contra un 52.4 de los hombres, p = 0.21. Las mujeres mostraron un mayor riesgo de sangrado (CRUSADE), sin diferencias en el riesgo isquémico (GRACE y TIMI). Se usaron stents farmacoactivos con más frecuencia en mujeres (88.9 vs. 75.5%, p = 0.04). Se observó una tendencia de menor prescripción del ticagrelor en mujeres (42.6 vs. 50.9%, p = 0.29) en favor de un mayor uso del clopidogrel. No se identificaron diferencias en cuanto a la prescripción del prasugrel. Las mujeres presentaron al año una menor mortalidad (1.4 vs. 6.7%, p = 0.19), aunque mayor sangrado (23.3 vs. 17.4%, p = 0.27). Conclusiones: En este estudio de pacientes consecutivos con SCA tratados con stent se registró una mayor prescripción de clopidogrel en las mujeres que en los hombres. Las mujeres presentaron una menor incidencia anual de mortalidad, pero mayor sangrado en comparación con los hombres, no significativo.
Abstract Aims and objective: Impact of sex-related differences in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention and treated with new P2Y12 inhibitors is not adequately characterised. We aimed to analyse gender-based differences in dual antiplatelet therapy, and adverse cardiovascular events and bleeding. Materials and methods: Prospective-observational study of the consecutive ACS patients treated with stent from July 2016 to January 2016, with a follow-up of 1 year. Results: We examined 283 patients, 75 (26.5%) women and 208 (73.5%) men. Women were older than men (71 ± 13 vs. 66,5 ± 13 years). There were 44% of women and 52% of men presenting with ST-elevation ACS (p = 0.21). Women had a higher bleeding risk (CRUSADE), without differences in the ischaemic risk (GRACE and TIMI). More women were treated with drug-eluting stent (88.9 vs. 75.5%, p = 0.04). There was a lower rate of ticagrelor prescription in women (42.6 vs. 50.9%, p = 0.29), in favour of clopidogrel. No differences were observed in prasugrel prescription. No significant differences were observed after a year of follow up, but women had a tendency towards lower mortality (1.4 vs. 6.7%, p = 0.19) and higher bleeding rates (23.3 vs. 17.4%, p = 0.27). Conclusions: In our study of patients presenting with ACS treated with stent, clopidogrel was preferred in women, whereas ticagrelor was the most frequent prescription in men. No significant differences were noted in clinical outcomes, but women experienced a tendency towards less mortality and more bleeding events.
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Stents , Acute Coronary Syndrome/therapy , Purinergic P2Y Receptor Antagonists/administration & dosage , Percutaneous Coronary Intervention/methods , Prognosis , Practice Patterns, Physicians'/statistics & numerical data , Ticlopidine/administration & dosage , Sex Factors , Prospective Studies , Acute Coronary Syndrome/mortality , Drug-Eluting Stents , Clopidogrel/administration & dosage , Ticagrelor/administration & dosage , Hemorrhage/epidemiologyABSTRACT
Resumen Introducción: La llegada de los anticoagulantes directos (ACD) ha supuesto un cambio en el tratamiento de la fibrilación auricular no valvular (FANV) en los últimos años. Los objetivos de este estudio son determinar el grado de control de la anticoagulación con antivitamina K (AVK) y su posible implicación en efectos cardiovasculares adversos mayores (ECAM) y evaluar las diferencias entre el grupo en tratamiento con AVK respecto del grupo con ACD. Pacientes y métodos: Estudio de cohorte prospectivo que incluyó a pacientes consecutivos diagnosticados con FANV valorados en el Servicio de Cardiología con un seguimiento de 18 meses. Se analizaron diferencias demográficas, clínicas y analíticas entre grupos, incluido el grado de control de la anticoagulación del grupo AVK y su posible relación con ECAM. Resultados: Se incluyó a 273 pacientes: 46.5% tratados con AVK, 42.5% con ACD y 11% sin tratamiento anticoagulante. El control de la anticoagulación con AVK fue del 62.1%, sin diferencias en ECAM en función de control. El grupo ACD presentó menos ECAM que el grupo de AVK (13.4 vs. 4.3%; HR, 0.90; 0.83-0.98; p = 0.01), con una menor mortalidad cardiovascular (0.0 vs. 5.5%; HR, 0.94; 0.90-0.98; p = 0.01) y total (0.9 vs. 12.6%; HR, 0.88; 0.82-0.94; p menor que 0,01), aunque sin diferencias significativas en eventos hemorrágicos (0.9 vs. 4.7%; p = 0.07) ni isquémicos (2.6 vs. 0.8%; p = 0.27). Discusión: Los pacientes con AVK poseen un perfil clínico diferente en comparación con los que reciben ACD. El control de anticoagulación del grupo de AVK fue inadecuado en casi la mitad de los casos. El grupo de AVK presentó más ECAM que el grupo de ACD.
Abstract Introduction: The arrival of direct-acting oral anticoagulants (DOACs) has led to a change in the management of non-valvular atrial fibrillation (NVAF) in recent years. The objectives of this study are to determine the level of therapeutic control of anticoagulation with vitamin K antagonists (VKA) and its possible involvement in major adverse cardiovascular events (MACE) and to evaluate differences between the group on VKA with respect to the group on DOACs. Patients and methods: Prospective cohort study that included consecutive patients diagnosed with NVAF in Cardiology Consultations with a clinical follow-up of 18 months. Demographic, clinical and analytical differences between groups were analyzed, including the level of therapeutic control of anticoagulation on the VKA group and its association with MACE. Results: Overall, 273 patients were included: 46.5% on VKA, 42.5% on DOACs, 11% without antithrombotic treatment. Patients on VKA spent 62.1% of their time within therapeutic range (TTR by the Rosendaal formule). There were no differences in MACE depending on anticoagulation control. The DOACs group presented lesser MACE rate than the VKA group (13.4 vs. 4.3%; 0.90; HR 0.90; 0.83-0.98 p = 0.01) with lower cardiovascular mortality (0.0 vs. 5.5%; HR, 0.94; 0.90-0.98; p = 0.01) and total mortality (0.9 vs. 12.6%; HR, 0.88; 0.82-0.94; p less 0.01) although without significant differences in hemorrhagic (0.9 vs. 4.7 %; p = 0.07), or ischemic events (2.6 vs. 0.8%, p = 0.27). Conclusions: Patients on VKA have a different clinical profile than those who receive DOACs. Patients on VKA have an inadequate control of the anticoagulation in quite the half of the cases. The VKA group presented more MACE than the DOACs group.
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Aged, 80 and over , Atrial Fibrillation/drug therapy , Vitamin K/antagonists & inhibitors , Factor Xa Inhibitors/administration & dosage , Anticoagulants/administration & dosage , Atrial Fibrillation/complications , Cardiovascular Diseases/epidemiology , Administration, Oral , Prospective Studies , Cohort Studies , Follow-Up Studies , Factor Xa Inhibitors/adverse effects , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Anticoagulants/adverse effectsABSTRACT
RESUMEN Introducción: la hemorragia digestiva alta ocurre por una lesión sangrante localizada entre el esfínter esofágico superior y el ángulo de Treitz. Objetivo: determinar el comportamiento del tratamiento endoscópico del sangrado digestivo alto por úlcera péptica, en el departamento de Gastroenterología del Hospital Universitario Comandante "Faustino Pérez". Materiales y métodos: se realizó un estudio descriptivo, prospectivo para evaluar el resultado del tratamiento endoscópico en el sangrado digestivo alto por úlcera péptica en el Hospital Universitario Comandante "Faustino Pérez" de Matanzas, de enero del 2016 a febrero del 2018. El tratamiento endoscópico fue la inyectoterapia con epinefrina al 1:10000. Se analizaron las variables: grupo de edades, sexo, resultado del tratamiento endoscópico, estigmas endoscópicos de sangrado, recidiva hemorrágica, mortalidad directa, necesidad de cirugía, estadía hospitalaria y cantidad de unidades transfusionales. Resultados: se constató un predominio de pacientes masculinos (87.5 %), menores de 60 años (70%). Prevalecieron los pacientes con estigmas endoscópicos de sangrado activo venoso (45%). La terapia endoscópica tuvo un resultado satisfactorio (92.5%) en su mayoría. La ocurrencia de resangrado (45%), mortalidad directa por hemorragia digestiva, promedio de estadía hospitalaria, cantidad de unidades transfusionales y necesidad de intervención quirúrgica de urgencia (17.5%), resultó similar a los estudios reportados, demostrando que la inyectoterapia endoscópica aún constituye una opción eficaz si no se cuenta con otras terapias endoscópicas. Conclusiones: la mayoría de los casos tratados con inyectoterapia endoscópica tuvieron un sangrado activo venoso o Forrest IB que fue satisfactoria. La inyectoterapia no satisfactoria fue en pacientes con sangrado activo. La mortalidad directa relacionada con el sangrado fue infrecuente y en relación con el sangrado arterial. Se demostró que la inyectoterapia endoscópica aún constituye una opción eficaz si no se cuenta con otras terapias endoscópicas (AU).
SUMMARY Introduction: high digestive bleeding happens due to a bleeding lesion located between the upper anatomical sphincter of the esophagus and the angle of Treitz. Objective: to determine the endoscopic treatment behavior of high digestive bleeding caused by peptic ulcer, in the department of Gastroenterology of the University Hospital "Comandante Faustino Perez". Materials and methods: a prospective descriptive study was carried out to evaluate the result of the endoscopic treatment in high digestive bleeding caused by peptic ulcer in the University Hospital "Comandante Faustino Perez", of Matanzas, from January 2016 to February 2018. The endoscopic treatment was injecto-therapy with epinephrine at 1:10000. The analyzed variables were: age group, sex, result of the endoscopic treatment, bleeding endoscopic stigma, hemorrhagic relapse, direct mortality, surgery necessity, hospital staying, and quantity of transfusion units. Results: male patients (87.5 %), aged less than 60 years predominated. Patients with endoscopic stigma of venous active bleeding (45 %) prevailed. In most of cases, endoscopic therapy achieved satisfactory results (92.5 %). The authors found that bleeding relapse (45 %), direct mortality by digestive hemorrhage, average hospital staying, quantity of transfusion units and necessity of urgent surgeries (17.5 %) were similar to those reported in other studies. Conclusions: most cases treated with endoscopic injectotherapy had active venous or Forrest IB bleeding and treatment was satisfactory. Therapy was unsatisfactory in patients with active bleeding. The direct mortality related to bleeding was infrequent, and related to arterial bleeding. It was showed that endoscopic injectotherapy is still an efficacious option if other endoscopic therapies are not available (AU).
Subject(s)
Middle Aged , Aged , Peptic Ulcer/diagnosis , Endoscopy/statistics & numerical data , Hemorrhage/therapy , Peptic Ulcer/etiology , Behavior , Epinephrine/therapeutic use , Epidemiology, Descriptive , Prospective Studies , Hemorrhage/complications , Hemorrhage/diagnosis , Hemorrhage/epidemiologySubject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Young Adult , Pyrazoles/adverse effects , Pyridones/adverse effects , Vitamin K/antagonists & inhibitors , Venous Thromboembolism/prevention & control , Hemorrhage/epidemiology , Anticoagulants/adverse effects , Pyrazoles/therapeutic use , Pyridones/therapeutic use , Randomized Controlled Trials as Topic , Global Health , Incidence , Risk Factors , Factor Xa Inhibitors/adverse effects , Factor Xa Inhibitors/therapeutic use , Hemorrhage/chemically induced , Anticoagulants/therapeutic useABSTRACT
We aim to reassess the safety of the monopolar transurethral resection of the prostate (M-TURP) without suprapubic cystostomy at our institution over the past decade. This retrospective study was conducted in patients who underwent M-TURP at Peking University First Hospital between 2003 and 2013. A total of 1680 patients who had undergone M-TURP were identified, including 539 patients in the noncystostomy group and 1141 patients in the cystostomy group. After propensity score matching, the number of patients in each group was 456. Smaller reductions in hemoglobin and hematocrit (10.9 g vs 17.6 g and 3.6% vs 4.7%, respectively) were found in the noncystostomy group. In addition, patients undergoing surgery without cystostomy had their catheters removed earlier (4.6 days vs 5.2 days), required shorter postoperative stays in the hospital (5.1 days vs 6.0 days), and were at lower risk of operative complications (5.7% vs 9.2%), especially bleeding requiring blood transfusion (2.9% vs 6.1%). Similar findings were observed in cohorts of prostates of 30-80 ml and prostates >80 ml. Furthermore, among patients with a resection weight >42.5 g or surgical time >90 min, or even propensity-matched patients based on surgical time, those with cystostomy seemed to be at a higher risk of operative complications. These results suggest that M-TURP without suprapubic cystostomy is a safe and effective method, even among patients with larger prostates, heavier estimated resection weights, and longer surgical times.
Subject(s)
Aged , Humans , Male , Middle Aged , Blood Transfusion , Cystostomy/methods , Hematocrit , Hemoglobins/analysis , Hemorrhage/epidemiology , Intraoperative Complications/epidemiology , Postoperative Complications/epidemiology , Propensity Score , Prostatectomy/methods , Prostatic Neoplasms/surgery , Retrospective Studies , Transurethral Resection of Prostate/methods , Treatment OutcomeABSTRACT
Resumo OBJETIVO Analisar associações entre discriminadores do Sistema de Triagem de Manchester e Diagnósticos de Enfermagem em pacientes adultos, classificados com prioridade clínica I (emergência) e II (muito urgente). MÉTODO Estudo transversal realizado na unidade de emergência do sul do Brasil, entre abril e agosto de 2014. Amostra de 219 pacientes. Os dados foram coletados no prontuário online e analisados estatisticamente, com teste exato de Fisher ou qui-quadrado. RESULTADOS Encontrou-se 16 discriminadores e 14 diagnósticos de enfermagem. Houve associação entre sete discriminadores e cinco diagnósticos de enfermagem do tipo foco no problema, dentre Dor precordial ou cardíaca com o diagnóstico Dor aguda. Também houve associação entre três discriminadores com quatro diagnósticos de enfermagem de risco, dentre Déficit neurológico agudo com o diagnóstico Risco de perfusão tissular cerebral ineficaz. CONCLUSÃO Existem associações significativas entre discriminadores do Sistema de Triagem de Manchester e diagnósticos de enfermagem mais frequentemente estabelecidos na Unidade de Emergência.
Resumen OBJETIVO Analizar asociaciones entre los discernidores del Sistema Triaje de Manchester y los Diagnósticos de Enfermería en pacientes adultos con prioridad clínica I (emergencia) y II (muy urgente). MÉTODO Estudio transversal realizado en la unidad de emergencia del sur de Brasil, entre abril y agosto de 2014, con la muestra de 219 pacientes. La colecta de datos fue realizada en el prontuario online de los pacientes. El análisis estadístico fue realizado con el uso del Test Exacto de Fisher o chi-cuadrado. RESULTADOS Fue identificado el uso de 16 discernidores y 14 diagnósticos de enfermería. Hubo una asociación entre siete discernidores y cinco diagnósticos de enfermería del tipo foco en el problema, entre estos Dolor precordial o cardíaca y Dolor agudo. También hubo asociación entre tres discernidores y cuatro diagnósticos de enfermería de riesgo, entre estos Déficit neurológico agudo con el diagnóstico Riesgo de perfusión tisular cerebral ineficaz. CONCLUSIÓN Existen asociaciones significativas entre los discernidores del Sistema Triaje de Manchester y los diagnósticos de enfermería más frecuente establecidos en la Unidad de Emergencia.
Abstract OBJECTIVE To analyze the association between Manchester Triage System flowchart discriminators and nursing diagnoses in adult patients classified as clinical priority I (emergency) and II (very urgent). METHOD Cross-sectional study conducted in an emergency department in southern Brazil between April and August 2014. The sample included 219 patients. Data were collected from online patient medical records and data analysis was performed using Fisher's exact test or the chi-square test. RESULTS 16 discriminators and 14 nursing diagnoses were identified. Associations were found between seven discriminators and five problem-focused nursing diagnoses, including the discriminator Cardiac pain and the diagnosis Acute pain. Three discriminators were associated with four risk nursing diagnoses, among these Acute neurological deficit with the diagnosis Risk of ineffective cerebral tissue perfusion. CONCLUSION Significant associations were found between Manchester Triage System discriminators and the nursing diagnoses most frequently established in the emergency department.
Subject(s)
Humans , Male , Female , Adult , Aged , Nursing Diagnosis , Triage , Emergency Nursing , Emergencies/nursing , Emergency Service, Hospital/organization & administration , Socioeconomic Factors , Chest Pain/diagnosis , Chest Pain/nursing , Chest Pain/epidemiology , Software Design , Brazil/epidemiology , Cross-Sectional Studies , Diagnosis-Related Groups , Dyspnea/diagnosis , Dyspnea/nursing , Dyspnea/epidemiology , Emergencies/epidemiology , Electronic Health Records , Hemorrhage/diagnosis , Hemorrhage/nursing , Hemorrhage/epidemiology , Hypoxia/diagnosis , Hypoxia/nursing , Hypoxia/epidemiology , Middle Aged , Nursing CareABSTRACT
Resumen: Introducción: La terapia antiagregante dual (TAD) con aspirina más clopidogrel o ticagrelor es fundamental para prevenir trombosis de stent y nuevos eventos cardiovasculares (CV) en pacientes sometidos a angioplastía coronaria (AC). Sin embargo, TAD se asocia a un riesgo aumentado de hemorragias, en particular cuando su uso se prolonga. Recientemente se han creado puntajes (DAPT, PRECISE-DAPT) que buscan estimar el riesgo de sangrado en pacientes con TAD por tiempo prolongado, los que quisimos evaluar en nuestra población. Métodos: Se utilizó la base de datos prospectiva de Prevención Cardiovascular del Hospital Clínico U. Católica, seleccionando pacientes sometidos a AC el año 2015. Se realizó una encuesta telefónica estandarizada para identificar episodios de sangrado definidos según clasificación ISTH, tiempo de uso de TAD y nuevos eventos CV. Se calcularon los puntajes DAPT y PRECISE-DAPT. Se usó pruebas de t de Student, test exacto de Fisher y curva ROC, según correspondiese, considerando significativa una p<0,05. Resultados: Se incluyeron 227 pacientes (edad 64,2±12,3 años, 22,5% mujeres), de los cuales el 69,6% eran hipertensos, 28,6% diabéticos, 26,9% fumadores y 5,3% insuficientes renales crónicos. En el 63% de los pacientes la AC fue por síndrome coronario agudo, se implantaron 1,4±0,7 stents/paciente y el 37% de los pacientes recibió sólo stents metálicos. Al momento de la encuesta, el seguimiento fue de 26±3 meses. Se registró un tiempo promedio de duración de TAD de 12,6±7,4 meses, con 99,1% de los pacientes recibiendo aspirina, 93,4% clopidogrel, 6,6% ticagrelor y 9,3% anticoagulantes orales. Hubo 35 (15,4%) nuevos eventos CV (revascularización 14, infarto 12, accidente cerebrovascular 2 y muerte 7) y 31 (13,6%) episodios de sangrados (criterio ISTH). De acuerdo con el criterio TIMI de sangrado se registraron 5 (2,2%) episodios graves, 9 (3,9%) leves y 17 (7,4%) menores. En 10 (4,4%) pacientes se modificó la TAD debido al sangrado. PRECISE-DAPT se asoció de manera significativa a los episodios de sangrado (p<0,01); tener un puntaje de alto riesgo (>25) aumentó más de 3 veces el riesgo de sangrado (OR 3,1 IC 1,4-7,1, p<0,01) y una curva ROC estableció que en la población estudiada el mejor punto de corte fue de 18 puntos (C-statistic 0,69) (Figuras 1A y B). El uso de TACO aumentó el riesgo (OR 3,4 IC 1,2-9,5, p=0,02). Si bien miden distintos parámetros, los puntajes de riesgo DAPT y PRECISE-DAPT se correlacionaron significativamente en nuestra cohorte (p<0,01). Conclusiones: En esta cohorte de la vida real se demuestra que la ocurrencia de sangramientos es un evento frecuente en pacientes con TAD, similar a la tasa de nuevos eventos CV, y por tanto debe ser un factor relevante a considerar al momento de la AC y la selección de la TAD. El puntaje PRECISE-DAPT es una herramienta útil para predecir sangrados, aunque nuestros resultados sugieren que en población chilena los valores de corte pueden ser algo menores que lo previamente publicado .
Abstracts: Background: Dual antiplatelet therapy (DAT) with aspirin plus clopidogrel or ticagrelor is essential for the prevention of stent thrombosis and new cardiovascular events in patients undergoing PCI. However, DAT is associated with an increased risk of bleeding, more so when it is used for prolonged time periods. Scores (DAPT, PRECISE-DAPT) developed to predict bleeding risk were evaluated in this study. Method: The prospective Cardiovascular Prevention database at Catholic University Hospital was used to select patients who underwent PCI followed by DAT during 2015. By phone contact information on bleeding episodes - according to the ISTH classification -, new cardiovascular events and DAT duration were collected. DAPT and PRECISE- DAPT scores were calculated. Student's t test, Fisher exact test and ROC analysis were used. Significance was established at p< 0.05. Results: 277 patients were included (age 64.2±12.3 y-o, 22.5% women). Hypertension was present in 66.9%, diabetes in 28.6%, smoking habit in 26.9% and renal failure in 5.3%. The indication for PCI was acute coronary syndrome in 63%, 1.4±0.7 stents per patient were implanted and 37% of patients received bare metal stents exclusively. Follow-up extended for 26±3 months. DAT was active for 12.6±7.4 months and 9.3% of patients received oral anticoagulant therapy. There were 35 (15.4%) new cardiovascular events (14 revascularizations, 12 myocardial infarctions, 2 CVA and 7 deaths). Conversely, there were 31 (13.6%) bleeding episodes. According to the TIMI classification, bleeding episodes were severe in 2.2%, mild in 3.9% and minor in 7.4%. In 4% of patients DAT was modified due to bleeding. PRECISE-DAPT score was significantly associated to bleeding episodes (p<0.01). A high score (>25) was associated with a 3-fold risk of bleeding (OR 3.1, CI 1.4-7.1 (p<0.01). Through ROC analysis the best PRECISE-DAPT cutting point in this cohort was 18 (C=0.69). The use of oral anticoagulation increased bleeding risk (OR 3.4 CI 1.2 - 9.5, p=0.02). DAPT and PRECISE-DAPT were significantly correlated (p<0.01). Conclusion: Bleeding is a frequent complication of DAT, similar to the risk of new cardiovascular events. PRECISE-DAPT score is useful to estimate the risk of bleeding, although this study suggests that in the studied population the cutting point may be somewhat lower than previously published.
Subject(s)
Humans , Male , Female , Middle Aged , Aged , Platelet Aggregation Inhibitors/adverse effects , Angioplasty, Balloon, Coronary/methods , Hemorrhage/chemically induced , Platelet Aggregation Inhibitors/therapeutic use , Cardiovascular Diseases/prevention & control , Aspirin/adverse effects , Prospective Studies , Surveys and Questionnaires , ROC Curve , Follow-Up Studies , Risk Assessment/methods , Clopidogrel/adverse effects , Ticagrelor/adverse effects , Hemorrhage/epidemiologyABSTRACT
Introducción: la hemorragia digestiva alta constituye un problema frecuente de salud en el mundo; así se comporta en Cuba, en la provincia Matanzas y en el hospital de estudio. Actualmente es considerada como causa mayor de morbimortalidad. Objetivo: determinar el comportamiento de la hemorragia digestiva alta en el Hospital Militar de Matanzas. Materiales y Métodos: se realizó una investigación descriptiva, en un periodo de cinco años que incluyó a todos los pacientes ingresados con ese diagnóstico, y los que durante su ingreso por otra causa presentaron episodios de hemorragia. El índice de Rockall permitió evaluar la necesidad de cirugía, recidiva y mortalidad. Resultados: la mayoría de los pacientes pertenecieron al grupo de riesgo intermedio. Los hombres fueron los más afectados, el grupo de tercera edad presentó mayor incidencia. La gastritis hemorrágica fue la primera causa de sangrado. La hipertensión arterial resultó ser el factor de riesgo relevante y el tabaquismo el hábito tóxico más frecuente. Conclusiones: como beneficio relevante se demostró la importancia de la endoscopia precoz para el diagnóstico de la causa, tratamiento y pronóstico de la hemorragia. Se observó una buena correlación entre el pronóstico del paciente al ingreso y su estado al final del tratamiento (AU).
Introduction: the high digestive hemorrhage is a frequent health problem in the world; it behaves the same in Cuba, in the province of Matanzas and in the hospital where the study was carried out. Currently it is considered a major cause of morbi-mortality. Objective: to determine the behavior of the high digestive bleeding in the Military Hospital of Matanzas. Materials and Methods: a descriptive research was carried out in a five-year period. It included all the patients admitted with that diagnosis and those who presented episodes of hemorrhage even if they were admitted by any other cause. The Rockall index allowed to assess the necessity of surgery, the recidivism and mortality. Results: most of the patients belonged to the intermediate risk group. Male patients were the most affected one; the group of elder people showed higher incidence. Hemorrhagic gastritis was the first cause of bleeding. Arterial hypertension was the relevant risk factor and smoking the most frequent toxic habit. Conclusions: as a relevant benefit it was showed the importance of precocious endoscopy for the diagnosis of the hemorrhage cause, treatment and prognosis. It was observed a good correlation between the patient´s prognosis at the admission and his status at the end of the treatment (AU).
Subject(s)
Humans , Male , Female , Hematemesis/pathology , Digestive System/pathology , Hemorrhage/epidemiology , Hematemesis/complications , Hematemesis/blood , Endoscopy, Digestive System/methods , Gastric Mucosa/injuries , Hemorrhage/complications , Hemorrhage/diagnosis , Hemorrhage/mortality , Hemorrhage/prevention & control , Hemorrhage/bloodABSTRACT
PURPOSE: Compared with warfarin, novel oral anticoagulants (NOACs) are convenient to use, although they require a blanking period immediately before radiofrequency catheter ablation for atrial fibrillation (AF). We compared NOACs and uninterrupted warfarin in the peri-procedural period of AF ablation. MATERIALS AND METHODS: We compared 141 patients treated with peri-procedural NOACs (72% men; 58+/-11 years old; 71% with paroxysmal AF) and 281 age-, sex-, AF type-, and history of stroke-matched patients treated with uninterrupted warfarin. NOACs were stopped 24 hours before the procedure and restarted on the same procedure day after hemostasis was achieved. RESULTS: We found no difference in the CHA2DS2-VASc (p=0.376) and HAS-BLED scores (p=0.175) between the groups. The preprocedural anticoagulation duration was significantly shorter in the NOAC group (76.3+/-110.7 days) than in the warfarin group (274.7+/-582.7 days, p<0.001). The intra-procedural total heparin requirement was higher (p<0.001), although mean activated clotting time was shorter (350.0+/-25.0 s vs. 367.4+/-42.9 s, p<0.001), in the NOAC group than in the warfarin group. There was no significant difference in thromboembolic events (1.4% vs. 0%, p=0.111) or major bleeding (1.4% vs. 3.9%, p=0.235) between the NOAC and warfarin groups. Minor stroke occurred in two cases within 10 hours of the procedure (underlying CHA2DS2-VASc scores 0 and 1) in the NOAC group. CONCLUSION: Pre-procedural anticoagulation duration was shorter and intra-procedural heparin requirement was higher with NOAC than with uninterrupted warfarin during AF ablation. Although the peri-procedural thromboembolism and bleeding incidences did not differ, minor stroke occurred in two cases in the NOAC group.
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Anticoagulants/therapeutic use , Atrial Fibrillation/complications , Catheter Ablation/methods , Follow-Up Studies , Hemorrhage/epidemiology , Heparin , Incidence , Postoperative Complications/epidemiology , Stroke/epidemiology , Thromboembolism/epidemiology , Treatment Outcome , Warfarin/administration & dosageABSTRACT
PURPOSE: Comatose elderly patients with acute neurological illness have a great risk of deep vein thrombosis (DVT). In this study, the incidence of DVT and the effectiveness of early initiation of treatment were evaluated in those patients. MATERIALS AND METHODS: Total 323 patients were admitted to our ward due to neurological diseases in one year, and 43 patients, whose Glasgow Coma Scale was or =60 years, were included in this study. D-dimer was measured on admission and day 7, and lower-extremity ultrasonography was performed on day 7. When DVT was positive, heparin treatment was initiated, and further evaluation of pulmonary embolism (PE) was conducted. Vena cava filter protection was inserted in PE-positive patients. Incidence of DVT and PE, alteration of D-dimer value, and effect of heparin treatment were analyzed. RESULTS: DVT was positive in 19 (44.2%) patients, and PE was in 4 (9.3%). D-dimer was significantly higher in DVT-positive group on day 7 (p<0.01). No DVT were identified in patients with ischemic disease, while 66.7% of intracerebral hemorrhage and 53.3% of brain contusion patients were DVT positive. Surgery was a definite risk factor for DVT, with an odds ratio of 5.25. DVT and PE disappeared by treatment in all cases, and no patients were succumbed to the thrombosis. CONCLUSION: Patients with hemorrhagic diseases or who undergo operation possess high risk of DVT, and initiation of heparin treatment in 7 days after admission is an effective prophylaxis for DVT in comatose elderly patients without causing bleeding.
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Acute Disease , Anticoagulants/adverse effects , Antifibrinolytic Agents/therapeutic use , Coma , Fibrin Fibrinogen Degradation Products/therapeutic use , Hemorrhage/epidemiology , Heparin/adverse effects , Incidence , Japan/epidemiology , Lower Extremity , Nervous System Diseases/epidemiology , Neurosurgical Procedures/adverse effects , Pulmonary Embolism/complications , Risk Factors , Venous Thrombosis/epidemiologyABSTRACT
Introdução: A discussão sobre a intensidade de varfarina em pacientes com síndrome antifosfolípide (SAF) permanece presente nos dias atuais. Objetivos: Avaliar qual intensidade de anticoagulação com varfarina está associada com maior redução de eventos tromboembólicos no tratamento de pacientes com SAF, assim como avaliar o risco de hemorragia nas diferentes modalidades de tratamento. Metodologia: Foi realizada uma revisão sistemática da literatura a partir de busca nas bases de dados eletrônicos: PubMed, LILACS e SciELO, sendo utilizadas as palavras-chave: treatment, warfarin, antiphospholipid syndrome, antiphospholipid antibody syndrome e suas respectivas traduções para o português, em diferentes combinações. Também foi realizada uma meta-análise com auxílio do programa Review Manager 5.2 da Cochrane. Resultados: Apenas dois artigos preencheram os critérios para inclusão neste estudo. Em relação ao principal desfecho avaliado neste trabalho, os dois estudos apresentaram valores similares, demonstrando maior frequência de eventos trombóticos nos grupos de alta intensidade. A análise comparativa dos ensaio clínicos randomizados avaliados demonstrou um risco trombótico aumentado para aqueles pacientes que receberam intervenção com varfarina em alta intensidade. Outro achado da meta-análise foi a maior ocorrência de hemorragia menor também no grupo experimental, que recebeu varfarina mantendo Razão Normalizada Internacional (RNI) > 3. Conclusão: Nos indivíduos com SAF e predominância de eventos venosos, o uso de anticoagulação em moderada intensidade (MI) (RNI: 2-3) está mais indicado. Por outro lado, essa evidência ainda não pode ser estendida aos pacientes com eventos arteriais, pela limitada representação dessa amostra de sujeitos nos dois estudos clínicos incluídos nesta meta-análise. .
Introduction: Discussion about the intensity of warfarin in patients with antiphospholipid syndrome (APS) remains present in our days. Objectives: To evaluate which intensity of anticoagulation with warfarin is associated with a greater reduction of thromboembolic events in the treatment of patients with APS, as well as assess the risk of bleeding in the different treatment modalities. Methodology: A systematic review of the literature was carried out with search from electronic databases: PubMed, LILACS and SciELO, with the use of the key-words: treatment, warfarin, antiphospholipid syndrome, antiphospholipid antibody syndrome and their respective translations into Portuguese, in different combinations. In addition, a meta-analysis with the aid of Review Manager 5.2 software by Cochrane was performed. Results: Only two articles met the inclusion criteria for this study. Regarding the main outcome assessed in this study, the two studies showed similar values, indicating higher frequency of thrombotic events in high-intensity groups. The comparative analysis of the randomized clinical trial evaluated showed an increased thrombotic risk for those patients who received intervention with high-intensity warfarin. Another finding of the meta-analysis was the higher incidence of minor bleeding, also in the experimental group, that received warfarin keeping International Normalized Ratio (INR) > 3. Conclusion: In individuals with APS and prevalence of venous events, the use of moderate intensity (MI) anticoagulation (INR: 2-3) is the most suitable. However, this evidence cannot yet be extended to patients with arterial events, due to the limited representation of this sample of subjects in the two clinical trials included in this meta-analysis. .
Subject(s)
Humans , Anticoagulants/administration & dosage , Antiphospholipid Syndrome/complications , Thrombosis/drug therapy , Thrombosis/etiology , Warfarin/administration & dosage , Anticoagulants/adverse effects , Hemorrhage/chemically induced , Hemorrhage/epidemiology , Risk Assessment , Warfarin/adverse effectsABSTRACT
Laparoscopic mini-gastric bypass surgery is a safe and simple surgical intervention for treating morbid obesity and diabetes mellitus and is now being performed more frequently. Radiologists must be critical in their postoperative evaluation of these patients. In this pictorial review, we explain and illustrate the surgical technique, normal postoperative anatomy, and associated complications as seen on imaging examinations, including fluoroscopy and computed tomography.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Anastomotic Leak/epidemiology , Cholelithiasis/epidemiology , Constriction, Pathologic/epidemiology , Diabetes Mellitus/therapy , Fluoroscopy , Gastric Bypass/methods , Hemorrhage/epidemiology , Laparoscopy , Obesity, Morbid/surgery , Stomach/diagnostic imaging , Tomography, X-Ray ComputedABSTRACT
Los pacientes anticoagulados crónicamente que son sometidos a cirugías electivas requieren la suspensión temporaria de los antagonistas de vitamina K. El objetivo del presente trabajo fue evaluar la incidencia de eventos tromboembólicos y hemorrágicos en pacientes anticoagulados sometidos a un procedimiento invasivo, aplicando un protocolo de manejo de anticoagulación en el perioperatorio. Se realizó un estudio descriptivo, con datos obtenidos de manera prospectiva, donde se incluyeron mayores de 18 años que ingresaron para la realización de una cirugía electiva. Recibieron sustitución con enoxaparina aquellos con fibrilación auricular(FA) de moderado y alto riesgo de evento tromboembólico, pacientes con reemplazo con válvula cardíaca mecánica(VCM) de moderado y alto riesgo de evento tromboembólico y con tromboembolismo venoso(TEV) de alto riesgo de evento tromboembólico. Se evaluaron los eventos embólicos y hemorrágicos en el perioperatorio. Setenta y ocho recibieron sustitución con enoxaparina en el perioperatorio, edad promedio de 69.4 ± 11.9 años. Veintiocho tenían FA (36.4%), 12 TEV (15.6%) y 37 VCM (48.1%). En el postoperatorio hubo un evento embólico (1.6%) y 12 eventos hemorrágicos (15.4%) de los cuales 10 fueron menores (12.8%) y 2mayores (2.6%). La seguridad de la sustitución con enoxaparina aún es cuestionable, y se deberán esperar estudios aleatorizados, comparando diferentes estrategias de sustitución con heparinas versus la suspensión del tratamiento anticoagulante en el período perioperatorio para una conclusión definitiva.
Anti-coagulated patients who undergo elective surgery require temporary interruption of vitamin K antagonists. The aim of this study was to evaluate the incidence of thromboembolic events and bleeding complications in anti-coagulated patients undergoing elective invasive procedures by using an institutional management protocol. This was a descriptive study with prospective follow-up that included patients over 18 year old anti-coagulated with vitamin K antagonists, undergoing elective surgery. Those with atrial fibrillation (AF) at moderate and high risk of thromboembolic events, with mechanical heart valve (MCV) at moderate and high risk of thromboembolic events, and patients' venous thromboembolism (VTE) at high risk of thromboembolic events received bridging therapy with enoxaparin. Embolic and bleeding events in the pre-operative period were recorded. Seventy- eight received bridging, mean age 69.4 ± 11.9 years. Twenty-eight had AF (36.4 %), 12 had VTE (15.6 %) and 37 had MCV (48.1 %). Postoperatively, 1 embolic event (1.6 %) and 12 bleeding events (15.4 %) were documented, of which 10 were minor (12.8 %) and 2 major (2.6 %). The safety of bridging therapy is still under debate, and we should await the result of randomized studies comparing different strategies of bridging vs. interruption of anticoagulant therapy in the pre-operative period prior to reaching a definitive conclusion.
Subject(s)
Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Elective Surgical Procedures/methods , Hemorrhage/epidemiology , Perioperative Care/methods , Thromboembolism/epidemiology , Vitamin K/antagonists & inhibitors , Anticoagulants/therapeutic use , Atrial Fibrillation/surgery , Enoxaparin/therapeutic use , Follow-Up Studies , Hemorrhage/drug therapy , Hemorrhage/prevention & control , Incidence , Postoperative Period , Prospective Studies , Risk Assessment , Risk Factors , Thromboembolism/drug therapy , Thromboembolism/prevention & controlABSTRACT
Identificar o perfil sociodemográfico e analisar a razão da mortalidade materna (RMM) por causas hipertensivas e hemorrágicas no Estado do Ceará. Estudo epidemiológico e documental. Realizado na Secretária de Saúde do Ceará, no banco de dados do Sistema de Informação da Mortalidade Materna, referente ao período de 2001 a 2010, constituindo-se de 356 registros de óbitos maternos. As mulheres em sua maioria, que foram a óbito por causas hipertensivas e hemorrágicasapresentaram idade entre 20-34 anos, possuíam de 1 a 7 anos de estudo, de etnia parda, solteiras e residiam no interior do Estado. O momento do óbito deu-se predominantemente no período gestacional. A RMM manteve-se ascendente entre 2001 - 2010. A mortalidade materna por causas hipertensivas e hemorrágicas é um grave problema de saúde pública, sendo necessário reduzi-la para melhorar os indicadores de saúde.
This study identifies social and demographic profiles and analyzes Maternal Mortality Ratio (MMR) from hypertensive and hemorrhagic causes in Ceará, Brazil. Epidemiologic and documentary study. It was conducted on the Information System of Maternal Mortality database at the Secretary of Health of the state of Ceará, Brazil, and encompassed the years 2001 to 2010, with 356 records of maternal deaths. Most women who died from hypertensive and hemorrhagic causes aged between 20-34 years, had 1-7 years of formal education, were mulatto, single, and resided in the backlands of the state. Death occurred predominantly during pregnancy. MMR moved up from 2001 to 2010. Maternal mortality from hypertensive and hemorrhagic causes is a serious public health problem and the decrease of existing levels is required to improve health indicators.
Describir el perfil sociodemográfico y analizar la tasa de mortalidad materna (TMM) provocados por hipertensión yhemorragia en el Estado de Ceará - Brasil. Estudio epidemiológico y documental. Realizado en la Secretaría de Salud de Ceará, en la base de datos del Sistema de Información de la Mortalidad Materna para el período de 2001 a 2010, convirtiéndose en356 registros de muertes maternas. Las mujeres en su mayoría, que murieron tenían entre 20 a 34 años, tenían de 1-7 años de estudio, mulatas, solteras y residentes en el interior del Estado. El momento de la muerte se produjo principalmente durante el embarazo. La TMM se mantuvo alta desde 2001 hasta 2010. La mortalidad materna por causa de hipertensión y hemorragias es un problema grave de salud pública, siendo necesario reducirla para mejorar los indicadores de salud.
Subject(s)
Humans , Male , Female , Young Adult , Hemorrhage , Hemorrhage/epidemiology , Hypertension, Pregnancy-Induced , Hypertension, Pregnancy-Induced/epidemiology , Maternal Mortality , Brazil , Epidemiology, Descriptive , Cross-Sectional StudiesABSTRACT
OBJECTIVES: to determine the prevalence of pulmonary hemorrhage in newborns and evaluate the associated risk factors and outcomes. METHODS: this was a retrospective case-control study involving 67 newborns who met the criteria for pulmonary hemorrhage. A control was selected for each case: the next-born child of the same gender, similar weight (± 200 g) and gestational age (± 1 week), with no previous pulmona ry hemorrhage and no malformation diagnosis. Factors previous to pulmonary hemorrhage onset, as well as aspects associated to the condition, were assessed. RESULTS: the prevalence was 6.7 for 1,000 live births, and the rates observed were: 8% among newborns < 1,500 g, and 11% among newborns < 1,000 g. Intubation in the delivery room (OR = 7.16), SNAPPE II (OR = 2.97), surfactant use (OR = 3.7), and blood components used previously to pulmonary hemorrhage onset (OR = 5.91) were associated with pulmonary hemorrhage. In the multivariate logistic regression model, only intubation in delivery room and previous use of blood components maintained the association. Children with pulmonary hemorrhage had higher mortality (OR = 7.24). Among the survivors, the length of stay (p < 0.01) and mechanical ventilation time were longer (OR = 25.6), and oxygen use at 36 weeks of corrected age was higher (OR = 7.67). CONCLUSIONS: pulmonary hemorrhage is more prevalent in premature newborns, and is associated with intubation in the delivery room and previous use of blood components, leading to high mortality and worse clinical evolution. .
OBJETIVOS : determinar a prevalência de hemorragia pulmonar entre os recém-nascidos internados no serviço e avaliar os fatores de risco e prognóstico associados. MÉTODOS: estudo retrospectivo caso-controle com 67 recém-nascidos que preencheram os critérios pré-estabelecidos de hemorragia pulmonar. Para cada caso, foi selecionado um controle: a próxima criança nascida do mesmo sexo, com semelhantes peso (± 200 g), idade gestacional (± 1 semana) e sem hemorragia pulmonar ou malformações. Foram estudados fatores prévios à ocorrência da hemorragia pulmonar e aspectos decorrentes do evento. RESULTADOS: a prevalência foi de 6,7 a cada 1.000 nascidos vivos, sendo de 8% entre os recém-nascidos menores que 1.500 g e de 11% entre os recém-nascidos menores que 1.000 g. A necessidade de intubação (IOT) em sala de parto (OR = 7,16), uso de hemoderivados previamente à ocorrência de hemorragia pulmonar (OR = 5,91), uso de surfactante (OR = 3,7) e SNAPPEII > 30 (OR = 2,97) foram associados à hemorragia pulmonar. No modelo de regressão logística multivariado, a necessidade de IOT (OR = 5,12) e uso de hemoderivados (OR = 4,2) mantiveram essa associação. As crianças com hemorragia pulmonar apresentaram maior mortalidade (OR = 7,24), entre as sobreviventes, maior tempo de internação (p < 0,01), mais uso de oxigênio com 36 semanas (OR = 7,67) e maior duração da ventilação mecânica (OR = 35,6). CONCLUSÃO: a hemorragia pulmonar é uma doença de maior prevalência em recém-nascidos pré-termos, e está associada à intubação em sala de parto e ao uso prévio de hemoderivados, acarretando maior mortalidade e pior evolução clínica das crianças. .
Subject(s)
Female , Humans , Infant, Newborn , Male , Hemorrhage/epidemiology , Intubation, Intratracheal/adverse effects , Lung Diseases/epidemiology , Apgar Score , Brazil/epidemiology , Case-Control Studies , Follow-Up Studies , Gestational Age , Hemorrhage/etiology , Hemorrhage/mortality , Infant, Premature , Lung Diseases/etiology , Lung Diseases/mortality , Odds Ratio , Prevalence , Pulmonary Surfactants/adverse effects , Respiration, Artificial , Retrospective Studies , Risk FactorsABSTRACT
PURPOSE: Although current guidelines recommend continuing the same antithrombotic strategy regardless of rhythm control after radiofrequency catheter ablation (RFCA) of atrial fibrillation (AF), anticoagulation has a risk of major bleeding. We evaluated the safety of switching warfarin to aspirin in patients with successful AF ablation. MATERIALS AND METHODS: Among 721 patients who underwent RFCA of AF, 608 patients (age, 57.3+/-10.9 years; 77.0% male, 75.5% paroxysmal AF) who had no evidence of AF recurrence at 3 months post-RFCA were included. We compared the thromboembolic and hemorrhagic events in patients for whom warfarin was switched to aspirin (ASA group; n=296) and patients who were kept on warfarin therapy (W group; n=312). RESULTS: There were no significant differences in CHA2DS2-VASc or HAS-BLED scores between the groups. In 30 patients in the ASA group and 37 patients in W group, AF recurred and warfarin was restarted or maintained during the 18.0+/-12.2 months of follow-up. There were no significant differences in thromboembolic (0.3% vs. 1.0%, p=0.342) and major bleeding incidences (0.7% vs. 0.6%, p=0.958) between ASA and W groups during the follow-up period. In the 259 patients with a CHA2DS2-VASc score > or =2, there were no significant differences in thromboembolism (0.8% and 2.2%, p=0.380) or major bleeding incidences (0.8% and 1.4%, p=0.640) between ASA and W groups. CONCLUSION: Switching warfarin to aspirin 3 months after successful RFCA of AF could be as safe and efficacious as long-term anticoagulation even in patients with CHA2DS2-VASc score > or =2. However, strict rhythm monitoring cannot be overemphasized.
Subject(s)
Aged , Female , Humans , Male , Middle Aged , Anticoagulants/therapeutic use , Aspirin/administration & dosage , Atrial Fibrillation/surgery , Catheter Ablation , Hemorrhage/epidemiology , Kaplan-Meier Estimate , Postoperative Complications/epidemiology , Retrospective Studies , Risk Assessment , Thromboembolism/epidemiology , Treatment Outcome , Warfarin/administration & dosageABSTRACT
El dolor es el síntoma más frecuente y que genera más temor en los pacientes y sus cuidadores en la etapa avanzada de la enfermedad oncológica. Estos niños también presentan otros síntomas que pueden provocar importante malestar y empeorar la sensación dolorosa. En nuestro medio no contamos con información en este ámbito, que permita optimizar el tratamiento de estos pacientes. Objetivo. Caracterizar síntomas distintos del dolor en pacientes con cáncer avanzado, controlados por el equipo de cuidado paliativo (CP) del Hospital Roberto del Río. Pacientes y método. Se revisaron 71 fichas clínicas de pacientes ingresados a CP entre abril de 2002 y diciembre de 2010. Se registraron las características demográficas y los diagnósticos fueron clasificados en leucemia aguda, tumores sólidos y tumores del sistema nervioso central (SNC). Se evaluó un listado de síntomas y sus frecuencias. Resultados. El síntoma más frecuente en los pacientes con leucemia aguda fue fiebre (15 por ciento), al igual que los pacientes con tumores sólidos (16 por ciento). En los pacientes con tumores SNC la alteración de conciencia fue el más frecuente (19 por ciento). Sobre el 70 por ciento de los pacientes tuvieron hasta cuatro síntomas y la evaluación de intensidad en la mayoría fue cualitativa. Conclusiones. Síntomas distintos del dolor son frecuentes y pueden producir gran incomodidad. Evaluarlos objetivamente permitiría un mejor manejo, favoreciendo con esto el control del dolor.
Pain is the most common symptom which generates most fear in patients and their caregivers in the advanced stage of cancer. These children also have other symptoms that can cause significant discomfort and exacerbate the sensation of pain. In Chile, there has been no evaluation of the intensity of these symptoms and their effect on pain, and relevant knowledge could improve patient treatment. Objective: Describe symptoms other than pain in patients with advanced cancer who were attended by the palliative care (PC) team at the Roberto del Rio Hospital. Patients and methods: We reviewed medical records of 71 patients admitted to PC between April 2002 and December 2010. We recorded demographic characteristics and diagnoses were classified into acute leukemia, solid tumors and tumors of the central nervous system (CNS). We evaluated a list of symptoms and their frequencies. Results: The most common symptom in patients with acute leukemia was fever (15 percent) as well as in patients with solid tumors (16 percent). In patients with CNS tumors alteration of consciousness was the most frequent (19 percent). Over 70 percent of patients had four or more symptoms and intensity assessment was mostly qualitative. Conclusions: Besides pain, other symptoms are common and can cause great discomfort. Objective assessment of these symptoms would allow better management of children and also optimize pain control.
Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Terminally Ill , Neoplasms/complications , Signs and Symptoms/statistics & numerical data , Palliative Care , Pain/epidemiology , Fever/epidemiology , Hemorrhage/epidemiology , Leukemia/complications , Central Nervous System Neoplasms/complications , Neoplasms/mortality , Child, Hospitalized/statistics & numerical data , Concurrent Symptoms , Consciousness Disorders/epidemiologyABSTRACT
La hemorragia es la complicación principal de los anticoagulantes orales, dicumarínicos o los nuevos agentes anti-Factor Xa y antitrombínicos. Se analizan los distintos factores de riesgo asociados a sangrado con los agentes clásicos y su vinculación probable con los nuevos fármacos. Se compara la incidencia de sangrado mayor en fibrilación auricular y en tromboembolismo venoso por ambos grupos de antitrombóticos. Además de las propiedades intrínsecas de los agentes clásicos y de los nuevos, serán las características de los pacientes y el correcto empleo terapéutico, los factores que impacten en la incidencia de sangrado en su uso diario, más allá de los datos publicados en los estudios clínicos.
Bleeding is the main complication of oral anticoagulants, anti-vitamin K or new drugs such as anti-factor Xa or anti-thrombin agents. Risk factors associated with bleeding during warfarin therapy are discussed. For the new drugs no published data is available yet. Comparative frequencies of major bleeding during anticoagulation in atrial fibrillation and venous thromboembolism are shown. Beyond the intrinsic properties of the classic and new agents, patients characteristics and co-morbidities and an appropriate management of the antithrombotic therapy will be the factors associated with bleeding incidence in real life.
Subject(s)
Humans , Anticoagulants/adverse effects , Hemorrhage/chemically induced , Venous Thromboembolism/drug therapy , Vitamin K/antagonists & inhibitors , Warfarin/adverse effects , Administration, Oral , Anticoagulants/therapeutic use , Atrial Fibrillation/drug therapy , Fibrinolytic Agents/adverse effects , Fibrinolytic Agents/therapeutic use , Hemorrhage/epidemiology , Incidence , Risk Factors , Risk Assessment/standards , Warfarin/therapeutic useABSTRACT
Introduction: The aim of this paper is to show our experience in the management of intractable bleeding facial trauma during the past 10 years to determine its impact on our environment and outline the basic principles of treatment. Methods: A retrospective study of all patients with maxillofacial trauma and uncontrollable bleeding from 1999 to 2009. Inclusion criteria were oro-nasal bleeding secondary to maxi-llofacial trauma requiring emergency treatment by a specialist, without other associated lesions that could be a source of bleeding. We obtained demographic information, mechanism of injury, diagnosis of injury, hemodynamic status, type and timing of tamponade, definitive surgical treatment, results and evolution. Results: 21 patients in the study period, a true incidence of 0.002 percent. 7 patients (33.3 percent) with trauma naso-septal; 5 (23.8 percent) with panfacial fractures, and 7 (33.3 percent) with variable involvement of the upper and middle face. Nine patients (42.9 percent) had isolated facial injuries. Only 5 patients (23.8 percent) had hemodynamic compromise. Thirteen patients (61.9 percent) required posterior nasal packing with or without another procedure to control bleeding. Eight patients (38.1 percent) required early reduction and internal fixation as definitive treatment. Conclusions: Maxillofacial trauma uncontrollable bleeding is uncommon and rarely is the primary cause of hypovolemic shock. It should be suspected in patients with facial injuries from hours bleeding. The packing, suturing of wounds and reduce/OTS are the mainstays of early treatment.
Introducción: El objetivo del presente trabajo es mostrar nuestra experiencia en el manejo de la hemorragia incoercible por trauma facial durante los últimos 10 años, para determinar su incidencia y delinear los principios básicos del tratamiento. Material y Método: Estudio retrospectivo de todos los pacientes con hemorragia incoercible por trauma maxilofacial entre 1999 y 2009. Criterios de inclusión fueron hemorragia oro-nasal secundaria a traumatismo maxilofacial, sin otras lesiones asociadas que pudieran ser fuente de hemorragia, que requirió de tratamiento de urgencia por un especialista. Se obtuvo información demográfica, mecanismo de injuria, diagnóstico del traumatismo, estado hemodinámico, tipo y momento del tratamiento especializado, tratamiento quirúrgico definitivo, resultados y evolución. Resultados: 21 pacientes en el período de estudio, con incidencia real de 0,002 por ciento. Destacan 7 pacientes (33,3 por ciento) con trauma nasoseptal, con o sin heridas faciales; 5 (23,8 por ciento) con fracturas panfaciales; 7 (33,3 por ciento) con compromiso variable del tercio superior y medio de la cara. Nueve pacientes (42,9 por ciento) presentaron lesiones faciales aisladas. 5 pacientes (23,8 por ciento) presentaron compromiso hemodinámico. Trece pacientes (61,9 por ciento) necesitaron un taponamiento nasal posterior, asociado o no a otro procedimiento para el control de la hemorragia. Ocho pacientes (38,1 por ciento) necesitaron reducción y osteosíntesis precoz como tratamiento definitivo. Conclusiones: La hemorragia incoercible por trauma maxilofacial es poco frecuente y rara vez es la causa primaria de shock hipovolémi-co. Se la debe sospechar especialmente en pacientes con lesiones faciales que llevan horas con sangrado, aún de poca cuantía, pero persistente. El taponamiento, sutura de heridas y reducción/OTS precoz son los pilares de su tratamiento.